ATC Group: A02BX02 Sucralfate

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A02BX02 in the ATC hierarchy

Level
Code
Title
1
Alimentary tract and metabolism
2
Drugs for acid related disorders
3
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
4
Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
5
A02BX02
Sucralfate

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route
Amount
ORAL - Oral
4 g

Active ingredients in A02BX02

Active Ingredient
Description

Sucralfate forms an ulcer adherent complex with the proteinaceous exudate of the ulcer site. This property enables sucralfate to form a protective barrier over the ulcer lesion giving sustained protection against the penetration and action of gastric acid, pepsin and bile.

Medicines in this ATC group

Drug
Countries

Estonia Finland Italy Turkey

New Zealand United States

Ecuador

France

Hong Kong

Hong Kong

Cyprus Estonia

Hong Kong Italy

Turkey

France Tunisia

South Africa

South Africa

South Africa

Mexico

Estonia Lithuania Poland

Related product monographs

Title
Type
Country
Structured Product Labeling (SPL)
US